The GPCR drugs with the highest potential of cancer cell line growth inhibition target adrenergic receptors, CC chemokine, glutamate, histamine, opioid, acetylcholine, and dopamine receptors (Figure 6D). This evidence concerns the gene LGR6 and cancer.